603087.SH
Gan & Lee Pharmaceuticals Co., Ltd.
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 67.74
−0.83%Year over year
Reported trailing growth
- Revenue
- +13.7%
- EBITDA
- —
- EBIT
- +34.4%
- EPS
- +23.2%
- Free cash flow
- —
- Operating cash flow
- +29.7%
Forward estimates
Based on analyst estimates
- Revenue
- +44.5%
- EBITDA
- +68.4%
- EPS
- +68.4%
Three-year CAGR
- Revenue
- +33.3%
- EBITDA
- +66.3%
- EBIT
- +93.8%
- Net income
- +83.4%
- EPS
- +79.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026